Edwards Lifesciences (EW) CFO sells 7,700 shares after option exercise

Rhea-AI Filing Summary

Edwards Lifesciences reported an insider stock transaction by its Chief Financial Officer, who serves as Corporate Vice President. On December 9, 2025, the executive exercised 7,700 employee stock options at an exercise price of $59.2567 per share, acquiring the same number of common shares. On the same date, the executive sold 7,700 shares of common stock at a weighted average price of $84.4691 per share. These trades were carried out under a Rule 10b5-1 trading plan adopted on July 29, 2025. After the reported transactions, the executive directly owned 39,898 shares of common stock and held 266,318 shares indirectly through a trust, along with 39,000 employee stock options that remained beneficially owned.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ullem Scott B.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M(1)		7,700	A	$59.2567	47,598	D
Common Stock	12/09/2025		S(1)		7,700	D	$84.4691(2)	39,898	D
Common Stock								266,318	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$59.2567	12/09/2025		M			7,700	05/08/2020	05/07/2026	Common Stock	7,700	$0.0000	39,000	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $84.09 to $85.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	12/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edwards Lifesciences (EW) disclose in this Form 4?

The filing reports that the Chief Financial Officer of Edwards Lifesciences exercised 7,700 employee stock options and sold 7,700 shares of common stock on December 9, 2025.

At what prices did the Edwards Lifesciences (EW) CFO exercise options and sell shares?

The employee stock options were exercised at an exercise price of $59.2567 per share. The resulting 7,700 shares of common stock were sold at a weighted average price of $84.4691 per share, with trades executed between $84.09 and $85.07.

How many Edwards Lifesciences (EW) shares does the reporting person own after the transaction?

Following the reported trades, the executive directly owned 39,898 shares of Edwards Lifesciences common stock and indirectly owned 266,318 shares through a trust, as well as 39,000 employee stock options.

Was the Edwards Lifesciences (EW) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan that the reporting person adopted on July 29, 2025.

What position does the reporting person hold at Edwards Lifesciences (EW)?

The reporting person is identified as an officer of Edwards Lifesciences, serving as Corporate Vice President and Chief Financial Officer.

What does Edwards Lifesciences (EW) note about the scope of this Form 4?

The remarks clarify that this Form 4 reflects changes in beneficial ownership only and does not identify other securities of the issuer beneficially owned by the reporting person.